Adoptive Cellular Immunotherapy Market
Adoptive Cellular Immunotherapy Market Scope: Industry Analysis, Market Size, Growth, Trends Till
Request Sample Report
Adoptive Cellular Immunotherapy Market Size and Growth
The Adoptive Cellular Immunotherapy market is experiencing robust growth, driven by rising cancer prevalence and advancements in cell therapy technologies. The global market size is projected to reach approximately $13 billion by 2026, with significant investments in research and development enhancing treatment modalities and expanding patient access to innovative therapies.
Companies Covered
(Covid 19 Impact Covered)
◍ Amgen Inc
◍ Autolus Therapeutics Plc
◍ Beijing Immunochina Medical Science & Technology Co Ltd
◍ Bellicum Pharmaceuticals Inc
◍ Bristol-Myers Squibb Co
◍ bluebird bio Inc
◍ CARsgen Therapeutics Ltd
◍ Celgene Corp
◍ Cell Medica Ltd
◍ Cellular Biomedicine Group Inc
◍ Celularity Inc
◍ Celyad SA
◍ Daiichi Sankyo Co Ltd
◍ Fosun Pharmaceutical AG
◍ Gilead Sciences Inc
The Adoptive Cellular Immunotherapy Market features key players like Amgen, Gilead Sciences, and Novartis, focusing on CAR-T therapies and innovations in T-cell engineering. These companies drive market growth through strategic partnerships, R&D investments, and expanding product pipelines, enhancing treatment options for cancer and immune disorders.
- Gilead Sciences: $26.3 billion (2022)
- Novartis: $49.2 billion (2022)
- Amgen: $26.8 billion (2022)
◍ Guangzhou Anjie Biomedical Technology Co Ltd
◍ Hangzhou Converd Co Ltd
Request Sample Report
◍ Hebei Senlang Biotechnology Inc Ltd
Market Segmentation
By Application
Hospital
Cancer Hospital
Centers for Disease Control and Prevention
Rehabilitation Center
Other
Request Sample Report
By Product
Market Growth
Request Sample Report
$ X Billion USD
